No evidence for PKC activation in stimulation of insulin secretion by phentolamine.
The possible role of protein kinase C (PKC) activation in the course of insulin secretion induced by the imidazoline phentolamine was investigated by measuring the insulin secretion of perifused mouse islets and of insulin-secreting HIT cells and by measuring the PKC activity of HIT cells. When normal mouse islets were perifused with the imidazoline phentolamine (32 microM) or the sulfonylurea glibenclamide (1 microM), neither phentolamine nor glibenclamide could produce a stimulation of secretion which was stronger than that elicited by a strong depolarization. Under the same conditions, tetradecanoylphorbolacetate (TPA, 50 nM), a known activator of PKC activity in pancreatic islets, markedly enhanced the secretion induced by K+ depolarization. Phentolamine also stimulated insulin secretion of superfused HIT cells. When PKC activity in HIT cells was down-regulated to 15% of the initial value by overnight exposure to TPA (50 nM), the stimulatory effect of TPA on secretion was virtually abolished, while phentolamine was still able to elicit a monophasic secretion. TPA (50 nM) induced the typical redistribution of PKC activity in HIT cells: within 2 min, the share of membrane-bound PKC activity rose from 26% to 87% of the total PKC activity, which remained unchanged. In contrast, phentolamine (32 microM) had no effect on PKC distribution, did not down-regulate PKC and had no effect on PKC activity once it was down-regulated by TPA. Thus, the recent suggestion that the insulinotropic effect of imidazolines involves an activation of PKC could not be verified for phentolamine.
Rustenbeck
I
I
Institute of Pharmacology and Toxicology, University of Göttingen, Germany.
Köpp
M
M
Polzin
C
C
Hasselblatt
A
A
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D002273:Carcinogens / Q000494:pharmacology; D002478:Cells, Cultured; D015536:Down-Regulation / Q000187:drug effects; D004789:Enzyme Activation / Q000187:drug effects; D005905:Glyburide / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism*; D051379:Mice; D010646:Phentolamine / Q000494:pharmacology*; D011493:Protein Kinase C / Q000378:metabolism*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D000959:Antihypertensive Agents; D002273:Carcinogens; D007004:Hypoglycemic Agents; D007328:Insulin; D011493:Protein Kinase C; D013755:Tetradecanoylphorbol Acetate; D005905:Glyburide; D010646:Phentolamine